CENTANY SUMMARY
Each gram of CENTANY (mupirocin ointment, 2%) contains 20 mg mupirocin in a soft white ointment base consisting of caprylic/capric/myristic/stearic triglyceride, castor oil, oleyl alcohol, and propylene glycol monostearate. Mupirocin is a naturally occurring antibiotic.
CENTANY (mupirocin ointment, 2%) is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes.
|
NEWS HIGHLIGHTS
Published Studies Related to Centany (Mupirocin Topical)
A Randomized Controlled Trial Comparing Mupirocin and Polysporin Triple Ointments in Peritoneal Dialysis Patients: The MP3 Study. [2011.12.01]
Background and objectivesInfectious complications remain a significant cause of peritoneal dialysis (PD) technique failure. Topical ointments seem to reduce peritonitis; however, concerns over resistance have led to a quest for alternative agents...
A double-blind, randomized, controlled trial of topical polysporin triple compound versus topical mupirocin for the eradication of colonization with methicillin-resistant Staphylococcus aureus in a complex continuing care population. [2009.09]
BACKGROUND: Intranasal mupirocin or Polysporin Triple (PT) ointment (polymyxin B, bacitracin, gramicidin), in combination with chlorhexidine body washes, have been used for eradicating methicillin-resistant Staphylococcus aureus (MRSA), but no comparative studies have been done... CONCLUSION: Both agents demonstrated poor efficacy and PT was significantly less efficacious than mupirocin at 12 weeks in eradicating MRSA from all sites.
Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. [2008.09]
OBJECTIVES/HYPOTHESIS: To examine the efficacy and tolerability of topical mupirocin for the management of surgically recalcitrant chronic rhinosinusitis (CRS) associated with Staphylococcus aureus infection. STUDY DESIGN: Prospective open-label pilot study... CONCLUSIONS: Nasal Lavage with 0.05% Mupirocin may represent an effective and well tolerated alternative treatment for postsurgical recalcitrant CRS.
A RANDOMIZED CONTROLLED TRIAL COMPARING MUPIROCIN VERSUS POLYSPORIN TRIPLEa FOR THE PREVENTION OF CATHETER-RELATED INFECTIONS IN PERITONEAL DIALYSIS PATIENTS (THE MP3 STUDY). [2008.01]
BACKGROUND: Peritonitis remains the most serious complication of peritoneal dialysis (PD). Gram-positive organisms are among the most common causes of PD peritonitis; however, recent trends show increasing rates of gram-negative and fungal infections.Discussion: The results of this study will help determine if the use of P3 is superior to mupirocin ointment in the prevention of catheter-related infections and will help guide evidence-based best practices.
Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience. [2008]
INTRODUCTION: The application of mupirocin to the exit-site in peritoneal dialysis (PD) patients decreases peritonitis and exit-site infection (ESI) considerably. However, long-term application of mupirocin may result in the development of methicillin- and mupirocin-resistant strains. In this study, we aimed to investigate the effect of once-a-week vs. thrice-a-week application of mupirocin on mupirocin and methicillin resistance in PD patients... CONCLUSION: The thrice-a-week application of mupirocin seems to be more efficient when compared to once-a-week application of mupirocin. Long-term application of mupirocin may cause the development of mupirocin- and methicillin-resistant strains, especially in CNS, which results in a difficulty for struggling against infections.
Clinical Trials Related to Centany (Mupirocin Topical)
A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban� Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions. [Completed]
The primary objective of this study is to determine the comparability of the safety and
efficacy of Mupirocin Calcium Cream, 2% and Bactroban® Cream in subjects with secondarily
infected traumatic skin lesions. It will also be determined whether the efficacy of each of
the active treatments is superior to that of the vehicle cream (placebo).
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection [Completed]
Staphylococcus aureus is a bacteria that causes serious, often life threatening infections
including pneumonia, wound, and bloodstream infections. Persons with AIDS are at high risk
for S. aureus infections. They are also at high risk for nasal carriage of S. aureus. In
fact, nasal carriage is a known risk factor for subsequent S. aureus infection. Topical
mupirocin, an antibiotic when applied to the anterior nares, is a safe, effective way to
eliminate S. aureus colonization. Some studies have shown that mupirocin can also decrease
the risk of S. aureus infection, but many of those studies utilized historical controls and
none were rigorously tested among AIDS patients over an extended period of time.
The main purpose of this randomized, double-blinded, placebo controlled study is to
determine if mupirocin can eliminate S. aureus nasal colonization in residents at PSI
(inpatient, drug rehabilitation facility for AIDS patients in the Bronx.) PSI residents
currently have a high incidence of S. aureus nasal colonization and infection. Nasal
cultures followed by twice daily application of mupirocin vs. placebo for five days will be
performed on a monthly basis for 8 months. the study will examine whether mupirocin
decreases the incidence of S. aureus infections and prevents S. aureus nasal colonization.
The study is important because it may show that mupirocin is an effective way to eliminate
nasal colonization and prevent S. aureus infections in AIDS patients, among those at highest
risk for serious S. aureus infection.
Hypothesis: Monthly application of mupirocin will reduce nasal colonization with S. aureus
Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting [Completed]
The hypothesis is that application of Mupirocin to the nose before and after coronary artery
bypass grafting surgery will reduce the incidence of surgical site infections.
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) [Completed]
This study will assess the nasal eradication of SA in healthy subjects following treatment
with mupirocin 2% (Bactroban 2% Nasal Ointment) twice daily for 5 days, by means of a
broth enriched culture microbial assay. The sensitivities of broth enrichment and plating
assay methods will be compared. The safety and tolerability of Bactroban 2% Nasal Ointment
will also be assessed.
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin [Completed]
We hypothesize the application of mupirocin or povidone-iodine to the nares is equally
effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective
is to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary
hip, knee, shoulder and elbow arthroplasty surgery and primary spinal fusion surgery
requiring implantation of prosthetic material, when the patient receives either nasal
mupirocin or nasal povidone-iodine prior to surgery.
Secondary study objectives include:
1. Measure hospital length of stay and re-admission rates in the mupirocin and
povidone-iodine groups.
2. Measure adverse events related to mupirocin and povidone-iodine.
3. Measure rate of SA resistance to mupirocin.
|
